1. A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma. Issue 5 (22nd March 2017) Authors: Berenson, James; Manges, Robert; Badarinath, Suprith; Cartmell, Alan; McIntyre, Kristi; Lyons, Roger; Harb, Wael; Mohamed, Hesham; Nourbakhsh, Ali; Rifkin, Robert Journal: American journal of hematology Issue: Volume 92:Issue 5(2017:May) Page Start: 460 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗